Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have earned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.50.

Separately, Leerink Partners began coverage on shares of Shattuck Labs in a research report on Monday. They issued an “outperform” rating and a $4.00 target price on the stock.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK traded up $0.05 during trading hours on Monday, reaching $1.24. The stock had a trading volume of 12,126 shares, compared to its average volume of 161,092. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76. The firm’s 50 day moving average is $1.25 and its 200-day moving average is $1.63. The stock has a market capitalization of $59.20 million, a price-to-earnings ratio of -0.81 and a beta of 1.66.

Institutional Trading of Shattuck Labs

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in Shattuck Labs by 63.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock worth $96,000 after purchasing an additional 10,667 shares during the period. Geode Capital Management LLC boosted its stake in Shattuck Labs by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after purchasing an additional 8,133 shares during the period. MetLife Investment Management LLC boosted its stake in Shattuck Labs by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the period. State Street Corp boosted its stake in Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after purchasing an additional 55,579 shares during the period. Finally, Barclays PLC boosted its stake in Shattuck Labs by 299.5% during the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock worth $189,000 after purchasing an additional 40,717 shares during the period. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.